Reaction profile
The FDA adverse-event record for lack of efficacy - nos
54,525 FDA reports name lack of efficacy - nos, a high-volume reaction in the CVM extract (VeDDRA 1039). Plate stamps and neighbourhood peers follow.
- #6 of 2,481
- by report volume (all reactions)
- 54,525
- reports citing this reaction
- 6.1%
- death-coded share
- Dog
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Lack of efficacy - NOS has 54,525 reports now versus 53,667 in that prior snapshot: 858 more (1.6%).
- Report change
- +858
- Death-coded reports
- +59
- Death-coded share
- +0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Lack of efficacy - NOS changesFDA AER · VeDDRA plate
Code 1039 VOL-MEGA
VOL-MEGA · DEATH-PAR · TOP-DECILE · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-MEGA 54,525 reports
- DEATH-PAR 6.1%
- TOP-DECILE #6/2481
- PHOTO-FINISH Lack of efficacy (end…
- SPECIES-DOG Dog · 42,966
- DRUG-LEAD Milbemycin Oxime… · 13,055
- DESK-WIDE 20 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Lack of efficacy (endoparasite) - heartworm (±1,755 reports)
Upper-third report volume drives the scale stamps on this plate; death-coded share and co-report peers follow. Not a clinical diagnosis.
High-volume neighbourhood around Lack of efficacy - NOS
Upper-third volume poles plus nearest peers, not a full reaction corpus board reprint.
Lack of efficacy - NOS: low death-coded share in the FDA AER plate
Signature read: 54,525 reports place Lack of efficacy - NOS in the upper third of FDA AER volume (#6 of 2,481). Report volume is upper-third scale: 54,525 named reports in the openFDA extract. Death-coded share is lower-third: 3,336 of 54,525 reports (6.1% of named reports). Nearest volume peer: Lack of efficacy (endoparasite) - heartworm (±1,755 reports). Lead species Dog (42,966). Lead co-reported drug Milbemycin Oxime + Spinosad (13,055).
Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Milbemycin Oxime + Spinosad appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
Nationwide reactions with similar profiles
Two openFDA-derived peer sets for Lack of efficacy - NOS, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).
Similar report volume
Nearest other reactions by FDA report count (54,525 here).
Similar death-coded share
Nearest other reactions by death-coded share (6.1% here), distinct from the volume row.
What to do with this reaction
- Compare Lack of efficacy - NOS's report profile against similar reactions nationwide. See similar reactions
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →